Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology. The Nanotrap® technology, coupled with existing research and clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres currently sells the Nanotrap® technology for use in a broad range of research and diagnostic applications.